Pfizer CEO says Trump's executive orders overhauling drug pricing will upend the industry.
designed to bring U.S. drug prices at least on par with their costs overseas.
Company spokeswoman Amy Rose later emailed CNBC to clarify that Bourla meant to say the orders were an "enormous distraction" for drugmakers working on coronavirus vaccines. A transcript service from data provider FactSet quoted Bourla, who is Greek and speaks with an accent, as saying the new orders would create "enormous disruption" in the industry.
Pfizer and German biotech company BioNTech said they began their late-stage human trial for a potential coronavirus vaccine on Monday.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Moderna, Pfizer Coronavirus Vaccines Begin Final-Stage TestingTwo of the most advanced experimental vaccines entered the pivotal phase of their studies, with the first subjects receiving doses of Moderna vaccine and Pfizer preparing to inject participants in its trial.
Weiterlesen »
Stocks making the biggest moves after hours: Pfizer, F5 Networks, Virgin Galactic and moreSee which stocks are posting big moves after the bell.
Weiterlesen »
Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday
Weiterlesen »
Pfizer, BioNTech could submit vaccine for approval by Oct – latest updatesPfizer, BioNTech could submit vaccine for approval by October. Other Covid19 updates: 🌍 Virus-linked hunger tied to 10,000 child deaths a month 🇧🇴 Bolivian prisoners riot over virus exposure 🇰🇪 Kenya extends lockdown by 30 days More here:
Weiterlesen »
Pfizer-BioNTech begin late-stage study of lead COVID-19 vaccine candidateGerman biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
Weiterlesen »
Pfizer profit falls 32% as global trial of COVID-19 vaccine candidate beginsPfizer Inc reported a 32% fall in second-quarter profit on Tuesday due to a dip in demand for some of its drugs from the COVID-19 pandemic and from rising competition, as the company and partner began a global study into a vaccine candidate to fight the health crisis.
Weiterlesen »